Skip to content
Home/Companies/Biotech/Cantargia

Cantargia

Biotech·Sweden·Exited 2015·Held 2yr
Entry
2013
Hold
2yr
Exit
2015

Who owns Cantargia?

Cantargia is a Swedish Biotech company, formerly owned by Sunstone Life Science Ventures, exited in 2015 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures III · 2007 · VC

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Exit Year
2015

More from Sunstone Life Science Ventures III

Other portfolio companies in the same fund.

MinervaX
MinervaX
Active
BiotechDenmark· 2014
Opsona Therapeutics
Exited 2019
BiotechIreland· 2013
Follicum
Exited 2014
BiotechSweden· 2012
to Swedish Growth Fund
Galecto
Exited 2020
BiotechDenmark· 2012
Orphazyme
Orphazyme
Exited 2017
BiotechDenmark· 2011
to Eurazeo
Vaximm
Exited 2022
BiotechGermany· 2011
to NEC OncoImmunity

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Cantargia?

Cantargia was formerly owned by Sunstone Life Science Ventures, exited in 2015. No current private equity owner is on file.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue